Lilly takes another shot at glucose-responsive insulin via Protomer takeout

Eli Lilly’s takeout of Protomer shows the pharma staying competitive in next-generation diabetes therapies, and signals it’s seen enough promise in Protomer’s glucose-responsive insulin program since its equity investment in the biotech last year. 

Eli Lilly and Co. (NYSE:LLY) previously acquired Glycostasis Inc. in 2016 for a glucose-responsive insulin technology, but the company has been mum on that program’s progress. ...